Donor selection for adoptive cell therapy with CD45RA- memory T cells for patients with coronavirus disease 2019, and dexamethasone and interleukin-15 effects on the phenotype, proliferation and interferon gamma release.

doi:10.1016/j.jcyt.2022.12.001

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Donor selection for adoptive cell therapy with CD45RA- memory T cells for patients with coronavirus disease 2019, and dexamethasone and interleukin-15 effects on the phenotype, proliferation and interferon gamma release.

Cytotherapy - 1 Mar 2023

Al-Akioui-Sanz Karima, Pascual-Miguel Bárbara, Díaz-Almirón Mariana, Mestre-Durán Carmen, Navarro-Zapata Alfonso, Clares-Villa Laura, Martín-Cortázar Carla, Vicario José Luis, Moreno Miguel Ángel, Balas Antonio, De Paz Raquel, Minguillón Jordi, Pérez-Martínez Antonio, Ferreras Cristina

Abstract excerpt

BACKGROUND AIMS: We have previously demonstrated the safety and feasibility of adoptive cell therapy with CD45RA- memory T cells containing severe acute respiratory syndrome coronavirus 2-specific T cells for patients with coronavirus disease 2019 from an unvaccinated donor who was chosen based on human leukocyte antigen compatibility and cellular response. In this study, we examined the durability of cellular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Viral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to COVID-19 Drug Treatment

Share to Dexamethasone

Share to Donor Selection

Share to Interferon-gamma

Share to Interleukin-15

Share to Leukocyte Common Antigens

Share to Vaccination

Source

Open in PubMed Open full text

Identifiers

PMID: 36585293
DOI: 10.1016/j.jcyt.2022.12.001
PMCID: PMC9742221

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Donor selection for adoptive cell therapy with CD45RA- memory T cells for patients with coronavirus disease 2019, and dexamethasone and interleukin-15 effects on the phenotype, proliferation and interferon gamma release.PMID 36585293Read ↗

Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapySemantic proximity Read ↗

Effect of cholecalciferol supplementation on inflammation and cellular alloimmunity in hemodialysis patients: data from a randomized controlled pilot trial.Semantic proximity Read ↗

Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19Semantic proximity Read ↗

The phenotypic changes of γδ T cells in COVID‐19 patientsSemantic proximity Read ↗

Detailed characterization of SARS-CoV-2-specific T and B cells after infection or heterologous vaccinationSemantic proximity Read ↗

A Phase I/II Study of Adoptive SARS-CoV-2 Specific T Cells in Immunocompromised Hosts with or at Risk of Severe COVID-19 InfectionSemantic proximity Read ↗

SUCCESSFUL MANUFACTURING OF CLINICAL-GRADE SARS-CoV-2 SPECIFIC T CELLS FOR ADOPTIVE CELL THERAPYSemantic proximity Read ↗

Immune responses and pathogenesis in persistently PCR-positive patients with SARS-CoV-2 infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.